Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Pharmacodynamics of Isavuconazole in a Rabbit Model of Cryptococcal Meningoencephalitis.

Kovanda LL, Giamberardino C, McEntee L, Toffaletti DL, Franke KS, Bartuska A, Smilnak G, de Castro GC, Ripple K, Hope WW, Perfect JR.

Antimicrob Agents Chemother. 2019 Jun 17. pii: AAC.00546-19. doi: 10.1128/AAC.00546-19. [Epub ahead of print]

2.

Population Pharmacokinetic Modeling of VL-2397, a Novel Systemic Antifungal Agent: Analysis of a Single- and Multiple-Ascending-Dose Study in Healthy Subjects.

Kovanda LL, Sullivan SM, Smith LR, Desai AV, Bonate PL, Hope WW.

Antimicrob Agents Chemother. 2019 May 24;63(6). pii: e00163-19. doi: 10.1128/AAC.00163-19. Print 2019 Jun.

PMID:
30988142
3.

Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials.

Andes DR, Ghannoum MA, Mukherjee PK, Kovanda LL, Lu Q, Jones ME, Santerre Henriksen A, Lademacher C, Hope WW.

Antimicrob Agents Chemother. 2018 Dec 21;63(1). pii: e01634-18. doi: 10.1128/AAC.01634-18. Print 2019 Jan.

4.

In Vitro Activity of Isavuconazole against Opportunistic Fungal Pathogens from Two Mycology Reference Laboratories.

Pfaller MA, Rhomberg PR, Wiederhold NP, Gibas C, Sanders C, Fan H, Mele J, Kovanda LL, Castanheira M.

Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e01230-18. doi: 10.1128/AAC.01230-18. Print 2018 Oct.

5.

Exposure-Response Analysis of Micafungin in Neonatal Candidiasis: Pooled Analysis of Two Clinical Trials.

Kovanda LL, Walsh TJ, Benjamin DK Jr, Arrieta A, Kaufman DA, Smith PB, Manzoni P, Desai AV, Kaibara A, Bonate PL, Hope WW.

Pediatr Infect Dis J. 2018 Jun;37(6):580-585. doi: 10.1097/INF.0000000000001957.

6.

A Phase 3 Study of Micafungin Versus Amphotericin B Deoxycholate in Infants With Invasive Candidiasis.

Benjamin DK Jr, Kaufman DA, Hope WW, Smith PB, Arrieta A, Manzoni P, Kovanda LL, Lademacher C, Isaacson B, Jednachowski D, Wu C, Kaibara A, Walsh TJ.

Pediatr Infect Dis J. 2018 Oct;37(10):992-998. doi: 10.1097/INF.0000000000001996. Erratum in: Pediatr Infect Dis J. 2018 Nov;37(11):1198.

7.

Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous Fungi.

Desai AV, Kovanda LL, Hope WW, Andes D, Mouton JW, Kowalski DL, Townsend RW, Mujais S, Bonate PL.

Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e01034-17. doi: 10.1128/AAC.01034-17. Print 2017 Dec.

8.

Combination Therapy with Isavuconazole and Micafungin for Treatment of Experimental Invasive Pulmonary Aspergillosis.

Petraitis V, Petraitiene R, McCarthy MW, Kovanda LL, Zaw MH, Hussain K, Shaikh N, Maung BBW, Sekhon NK, Hope WW, Walsh TJ.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e00305-17. doi: 10.1128/AAC.00305-17. Print 2017 Sep.

9.

Pharmacodynamics of Isavuconazole for Invasive Mold Disease: Role of Galactomannan for Real-Time Monitoring of Therapeutic Response.

Kovanda LL, Kolamunnage-Dona R, Neely M, Maertens J, Lee M, Hope WW.

Clin Infect Dis. 2017 Jun 1;64(11):1557-1563. doi: 10.1093/cid/cix198. Erratum in: Clin Infect Dis. 2017 Oct 15;65(8):1431-1433.

10.

Impact of Mucositis on Absorption and Systemic Drug Exposure of Isavuconazole.

Kovanda LL, Marty FM, Maertens J, Desai AV, Lademacher C, Engelhardt M, Lu Q, Hope WW.

Antimicrob Agents Chemother. 2017 May 24;61(6). pii: e00101-17. doi: 10.1128/AAC.00101-17. Print 2017 Jun.

11.

In vitro combination therapy with isavuconazole against Candida spp.

Katragkou A, McCarthy M, Meletiadis J, Hussain K, Moradi PW, Strauss GE, Myint KL, Zaw MH, Kovanda LL, Petraitiene R, Roilides E, Walsh TJ, Petraitis V.

Med Mycol. 2017 Nov 1;55(8):859-868. doi: 10.1093/mmy/myx006.

PMID:
28204571
12.

Prognostic value of galactomannan: current evidence for monitoring response to antifungal therapy in patients with invasive aspergillosis.

Kovanda LL, Desai AV, Hope WW.

J Pharmacokinet Pharmacodyn. 2017 Apr;44(2):143-151. doi: 10.1007/s10928-017-9509-1. Epub 2017 Feb 8. Review.

PMID:
28181136
13.

Isavuconazole Population Pharmacokinetic Analysis Using Nonparametric Estimation in Patients with Invasive Fungal Disease (Results from the VITAL Study).

Kovanda LL, Desai AV, Lu Q, Townsend RW, Akhtar S, Bonate P, Hope WW.

Antimicrob Agents Chemother. 2016 Jul 22;60(8):4568-76. doi: 10.1128/AAC.00514-16. Print 2016 Aug.

14.

Isavuconazonium sulfate: a new agent for the treatment of invasive aspergillosis and invasive mucormycosis.

Kovanda LL, Maher R, Hope WW.

Expert Rev Clin Pharmacol. 2016 Jul;9(7):887-97. doi: 10.1080/17512433.2016.1185361. Epub 2016 May 21. Review.

PMID:
27160418
15.

Pharmacodynamics of isavuconazole in experimental invasive pulmonary aspergillosis: implications for clinical breakpoints.

Kovanda LL, Petraitiene R, Petraitis V, Walsh TJ, Desai A, Bonate P, Hope WW.

J Antimicrob Chemother. 2016 Jul;71(7):1885-91. doi: 10.1093/jac/dkw098. Epub 2016 Apr 15.

16.

Pharmacokinetics and Concentration-Dependent Efficacy of Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis.

Petraitis V, Petraitiene R, Moradi PW, Strauss GE, Katragkou A, Kovanda LL, Hope WW, Walsh TJ.

Antimicrob Agents Chemother. 2016 Apr 22;60(5):2718-26. doi: 10.1128/AAC.02665-15. Print 2016 May.

17.

Population pharmacokinetics of micafungin and its metabolites M1 and M5 in children and adolescents.

Hope WW, Kaibara A, Roy M, Arrieta A, Azie N, Kovanda LL, Benjamin DK Jr.

Antimicrob Agents Chemother. 2015 Feb;59(2):905-13. doi: 10.1128/AAC.03736-14. Epub 2014 Nov 24.

18.

In vitro combination of isavuconazole with micafungin or amphotericin B deoxycholate against medically important molds.

Katragkou A, McCarthy M, Meletiadis J, Petraitis V, Moradi PW, Strauss GE, Fouant MM, Kovanda LL, Petraitiene R, Roilides E, Walsh TJ.

Antimicrob Agents Chemother. 2014 Nov;58(11):6934-7. doi: 10.1128/AAC.03261-14. Epub 2014 Aug 18.

19.

Clinical pharmacodynamic index identification for micafungin in esophageal candidiasis: dosing strategy optimization.

Andes DR, Reynolds DK, Van Wart SA, Lepak AJ, Kovanda LL, Bhavnani SM.

Antimicrob Agents Chemother. 2013 Nov;57(11):5714-6. doi: 10.1128/AAC.01057-13. Epub 2013 Aug 19.

20.

Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia.

Andes D, Ambrose PG, Hammel JP, Van Wart SA, Iyer V, Reynolds DK, Buell DN, Kovanda LL, Bhavnani SM.

Antimicrob Agents Chemother. 2011 May;55(5):2113-21. doi: 10.1128/AAC.01430-10. Epub 2011 Feb 7.

21.

Factors related to survival and treatment success in invasive candidiasis or candidemia: a pooled analysis of two large, prospective, micafungin trials.

Horn DL, Ostrosky-Zeichner L, Morris MI, Ullmann AJ, Wu C, Buell DN, Kovanda LL, Cornely OA.

Eur J Clin Microbiol Infect Dis. 2010 Feb;29(2):223-9. doi: 10.1007/s10096-009-0843-0. Epub 2009 Dec 15.

PMID:
20013016
22.

Safety and pharmacokinetics of repeat-dose micafungin in young infants.

Benjamin DK Jr, Smith PB, Arrieta A, Castro L, Sánchez PJ, Kaufman D, Arnold LJ, Kovanda LL, Sawamoto T, Buell DN, Hope WW, Walsh TJ.

Clin Pharmacol Ther. 2010 Jan;87(1):93-9. doi: 10.1038/clpt.2009.200. Epub 2009 Nov 4.

23.

Pharmacokinetics of an elevated dosage of micafungin in premature neonates.

Smith PB, Walsh TJ, Hope W, Arrieta A, Takada A, Kovanda LL, Kearns GL, Kaufman D, Sawamoto T, Buell DN, Benjamin DK Jr.

Pediatr Infect Dis J. 2009 May;28(5):412-5. doi: 10.1097/INF.0b013e3181910e2d.

24.

Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis.

Pappas PG, Rotstein CM, Betts RF, Nucci M, Talwar D, De Waele JJ, Vazquez JA, Dupont BF, Horn DL, Ostrosky-Zeichner L, Reboli AC, Suh B, Digumarti R, Wu C, Kovanda LL, Arnold LJ, Buell DN.

Clin Infect Dis. 2007 Oct 1;45(7):883-93. Epub 2007 Aug 29. Erratum in: Clin Infect Dis. 2008 Jul 15;47(2):302.

PMID:
17806055

Supplemental Content

Loading ...
Support Center